NDA 019931 · Bausch
Klaron
Sulfacetamide Sodium · Topical
Last checked: Nov 20, 2026Latest source record: Feb 16, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1996
Dec 23, 1996
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2
0 Phase 3, 0 recruiting
FAERS reports
580
250 serious, 15 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 31, 2020.
INDICATIONS Klaron Lotion is indicated in the topical treatment of acne vulgaris .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 23, 1996 Original approval · Type 3 - New Dosage Form Review
1 products under this application
- KLARON · SULFACETAMIDE SODIUM 10% · LOTION, TOPICAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Sulfacetamide" as an intervention, any sponsor and status, largest first.
Joseph B. Ciolino, MDAcademic, hospital or other
NCT02256969 · 45 participants · Start Oct 2014 · Primary completion Aug 2015
Drug: Blephamide; GenTeal PM Night-Time · For: Meibomian Gland Dysfunction
Sites: Boston, Massachusetts
Julio RamirezAcademic, hospital or other
NCT02099240 · 11 participants · Start Mar 6, 2014 · Primary completion Nov 7, 2018
Drug: oral antibiotics · For: Osteomyelitis
Sites: Louisville, Kentucky
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug hypersensitivity66
- drug ineffective55
- nausea36
- off label use35
- headache31
- pain30
- dyspnoea29
- rash28
- fatigue25
- weight decreased24
- vomiting20
- diarrhoea19
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 10 |
| 2006 | 3 |
| 2007 | 8 |
| 2008 | 5 |
| 2009 | 12 |
| 2010 | 20 |
| 2011 | 14 |
| 2012 | 18 |
| 2013 | 25 |
| 2014 | 13 |
| 2015 | 25 |
| 2016 | 49 |
| 2017 | 38 |
| 2018 | 42 |
| 2019 | 54 |
| 2020 | 31 |
| 2021 | 25 |
| 2022 | 49 |
| 2023 | 35 |
| 2024 | 32 |
| 2025 | 35 |
| 2026 | 35 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Acne and the cutaneous microbiome: A systematic review of mechanisms and implications for treatments.
Podwojniak A, Tan IJ, Sauer J, et al. · J Eur Acad Dermatol Venereol 2025 · Systematic Review
- Antibiotic prophylaxis for corneal abrasion.
Ng SM, Leslie L, Tzang CC, et al. · Cochrane Database Syst Rev 2025 · Systematic Review, Meta-Analysis
- Topical sulfacetamide vs oral erythromycin for neonatal chlamydial conjunctivitis.
Heggie AD, Jaffe AC, Stuart LA, et al. · Am J Dis Child 1985 · Clinical Trial, Comparative Study
- Topical sodium sulfacetamide/sulfur lotion.
Tarimci N, Sener S, Kilinç T · J Clin Pharm Ther 1997 · Clinical Trial, Controlled Clinical Trial
- Pilot investigation of the hydrating effects of topical acne medications.
Zhen Y, Stoudemayer M, Vamvakias G, et al. · J Drugs Dermatol 2007 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Perioral dermatitis: etiology and treatment.
Bendl BJ · Cutis 1976 · Clinical Trial, Comparative Study
Sponsor: Bausch
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.